Targeting the VEGF/VEGF receptor 2 (VEGFR2) pathway may improve the efficacy of checkpoint inhibitors by reprogramming the tumor microenvironment to be more immunosupportive or inflammatory [23]. Here, KDR is linked to neoplasm.